Story perspectives

Trump Administration Rejects Medicare Coverage for Weight Loss Drugs

4/4/2025

46 10

Summary

Story summary

The Trump administration has turned down a significant proposal to let Medicare and Medicaid cover weight loss drugs such as Wegovy and Zepbound, a decision that could have saved lives but would have cost $35 billion over a decade. While the Centers for Medicare and Medicaid Services may revisit this policy later, access to these crucial treatments remains restricted for now.

History

Historical Context

The Trump administration's rejection of Medicare and Medicaid coverage for weight loss drugs reflects ongoing debates about healthcare access and costs. Historically, similar resistance occurred during President Bill Clinton's healthcare reform efforts in the 1990s, which faced significant political backlash despite public support. This trend highlights persistent challenges in balancing healthcare affordability with the need for comprehensive treatment options, particularly for obesity-related health issues.

1 of 2

Story summary

The Trump administration has turned down a significant proposal to let Medicare and Medicaid cover weight loss drugs such as Wegovy and Zepbound, a decision that could have saved lives but would have cost $35 billion over a decade. While the Centers for Medicare and Medicaid Services may revisit this policy later, access to these crucial treatments remains restricted for now.

1 / 2